Results 11 to 20 of about 7,770 (204)
ESMO Open, 2018 Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
+9 more sources
Therapeutische Umschau, 2011 Die Bewertung von Biosimilars stellt eine Herausforderung für alle an der Zulassung und an der Arzneimittelauswahl Beteiligten im Gesundheitswesen dar. Bewertungskriterien sind wie bei allen Arzneimitteln Qualität, Wirksamkeit, Sicherheit/Verträglichkeit und Wirtschaftlichkeit.
openaire +6 more sources
Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption
Medicina, 2022 (1) Background: A biosimilar is a biologic medical product that has been approved by the United States Food and Federal Drug Administration (FDA) and is an almost identical copy of an original biologic product yet manufactured by a different company ...
John Hair +2 more
doaj +1 more source
Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective [PDF]
Global Journal on Quality and Safety in Healthcare, 2020 Biologics are significant drivers of globally escalating healthcare costs. Biosimilars have potential to offer cost savings with comparable efficacy and safety to innovator products and increase the access of treatment to more patients.
Mansoor A. Khan +4 more
doaj +1 more source
Blood Advances, 2017 : Immunogenicity of biotherapeutics and the elicitation of anti-drug antibodies are a key concern for their efficacy, pharmacokinetics, and safety.
Tina Rubic-Schneider +11 more
doaj +1 more source
Rheumatology International, 2014 Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F. +4 more
openaire +2 more sources
Arthritis Research & Therapy, 2019 Background ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).
Stanley Cohen +7 more
doaj +1 more source
Physicians’ perceptions of the uptake of biosimilars: a systematic review
BMJ Open, 2020 Objectives To examine physicians’ perceptions of the uptake of biosimilars.Design Systematic review.Data sources MedLine Ovid and Scopus databases at the end of 2018.Eligibility criteria Original scientific studies written in English that addressed ...
Katri Hämeen-Anttila +3 more
doaj +1 more source
The structure-function relationship of disulfide bonds in etanercept
Scientific Reports, 2017 Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis. Physicochemical and functional investigation of process fractions during development of the etanercept biosimilar GP2015 (Erelzi®) revealed a ...
William C. Lamanna +10 more
doaj +1 more source
JCO Global Oncology, 2021 PURPOSEBreast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]).
Heloísa M. Resende +7 more
doaj +1 more source